Mar 18 |
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
|
Mar 13 |
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
|
Mar 8 |
Inventiva resumes Phase 3 study for NASH drug, stock up 6%
|
Mar 7 |
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
|
Feb 22 |
Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
|
Feb 16 |
Inventiva drops after adverse event in Phase 3 trial for NASH drug
|
Feb 16 |
Yelp Reports Q4 Results, Joins Roku, Dropbox And Other Big Stocks Moving Lower In Friday's Pre-Market Session
|
Feb 15 |
Inventiva reports FY results
|
Feb 15 |
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
|